Clinical Trial Detail

NCT ID NCT02779283
Title Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

acute myeloid leukemia

Therapies

Dasatinib

Nilotinib

Ponatinib

Sorafenib

Cytarabine + Idarubicin

Sunitinib

Age Groups: adult

No variant requirements are available.